Effects of Cilostazol on Serum Lipid Concentrations and Plasma Fatty Acid Composition in Diabetic Patients with Peripheral Vessel Diseases

Abstract

Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects. We investigated the effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in diabetic patients with peripheral vessel diseases (PVD). The serum concentrations of total cholesterol (T-chol), triglycerides (TG), HDLcholesterol (HDL-C), Lp(a), remnant-like particlecholesterol (RLP-C) and plasma fatty acid composition were measured in 17 diabetic patients with PVD before and 1, 3, and 6 months after administration of cilostazol (200mg/day). Serum TG concentrations were significantly decreased after the administration. Plasma docosahexaenoic acids (DHA) levels were significantly increased after the administration. Other parameters showed no significant changes. Our findings suggested that cilostazol produced anti-atherosclerotic effects by decreasing TG and increasing DHA.